Optic Neuritis
Clinical Snapshot
Optic neuritis is acute inflammation of the optic nerve — most often an isolated, immune-mediated demyelinating event — and one of the most consequential "isolated" diagnoses in neurology and ophthalmology: in a substantial share of adults who present with it, this single episode turns out to be the first clinical manifestation of multiple sclerosis (MS).[1] This chapter is not primarily about treating a red or painful eye; it is about recognizing a pattern quickly enough to refer urgently, using the right imaging test not only to confirm the diagnosis but to genuinely stratify the patient's own long-term risk of MS, and understanding a treatment finding that is deliberately, instructively counterintuitive: the same drug class — corticosteroids — speeds up visual recovery by weeks when given intravenously, without changing the final visual outcome at all, while an oral-only course of the very same drug gives no benefit and specifically increases the risk of a new attack.[2][3]
The relative afferent pupillary defect (RAPD) is the single most useful bedside sign. In unilateral or clearly asymmetric optic neuritis, an RAPD should always be present; its absence should prompt you to reconsider the diagnosis rather than to document it as reassuring. See Recognize the Condition for the full examination pattern.
In the most detailed modern population-based accounting available — a 19-year cohort from Olmsted County, Minnesota — the age- and sex-adjusted incidence of optic neuritis was 4.0 per 100,000 people annually, with a median age at onset of 37.5 years and a clear female predominance (67% of cases).[4] Most cases in that cohort were either MS-associated (57% of all optic neuritis) or idiopathic, with no identifiable systemic cause found on a reasonable workup (29%); antibody-defined subtypes — MOG-IgG-associated disease (MOGAD, 5%) and AQP4-IgG-positive neuromyelitis optica spectrum disorder (NMOSD, 3%) — accounted for a much smaller share, but are disproportionately important to recognize because they change management in ways that genuinely matter (see Assessment & Diagnosis and Special Populations).[4]
Recognize the Condition
The classic triad
Acute optic neuritis presents with a recognizable triad: subacute, usually unilateral vision loss developing over hours to a few days (not seconds, and not present and stable for weeks beforehand); orbital or periocular pain that characteristically worsens with eye movement, present in the large majority of patients (87% in one Canadian case series); and a relative afferent pupillary defect (RAPD) on examination.[1] Of these three, the RAPD is the single most important bedside sign: it confirms that the visual pathway defect is asymmetric and lies in the optic nerve itself (or elsewhere anterior to the optic chiasm) rather than being explained by, for instance, a purely retinal problem or a bilateral, symmetric process. In a patient with unilateral or clearly asymmetric vision loss, the absence of an RAPD is itself a red flag that should prompt reconsideration of the diagnosis rather than being dismissed as a normal variant (see Red Flags for Referral).
Pupillary, colour vision, and visual field findings
Beyond the RAPD, colour vision is frequently affected out of proportion to the reduction in visual acuity — patients often describe colours, especially red, as looking washed out, faded, or "less bright" specifically in the affected eye. Asking a patient to compare the appearance of a red object (a pen cap, a phone case) between the two eyes is a simple, useful bedside test that can reveal this even when formal colour-vision testing is not available. Visual field loss is genuinely variable in pattern, but a central or cecocentral scotoma — a blind spot involving fixation, sometimes extending to and connecting with the physiologic blind spot — is the classic pattern; other patterns, including diffuse loss, arcuate defects, or altitudinal loss, can also occur and do not exclude the diagnosis on their own.
Fundoscopy: usually normal, not usually swollen
A genuinely useful teaching point, and a common source of missed or delayed diagnosis: the optic disc looks normal on fundoscopy in the majority of adult optic neuritis, because most inflammation is retrobulbar — behind the point the ophthalmoscope can see — summarized by the old teaching phrase "the patient sees nothing, and the doctor sees nothing." In the largest modern population-based series available, disc edema was absent in 64% and only mild in a further 25% of MS-associated optic neuritis, meaning close to nine in ten typical cases show little or no visible disc swelling at all.[4] A visibly swollen, hyperemic disc (papillitis, sometimes with peripapillary hemorrhage) is seen more often — and more severely — in MOG-IgG-associated disease specifically (moderate-to-severe edema in 67% of MOGAD cases, with peripapillary hemorrhage in a further 20%), making prominent disc swelling itself a genuine clue toward MOGAD rather than typical MS-associated optic neuritis.[4] Do not use a normal-looking disc to argue against the diagnosis, and do not use disc swelling alone to argue for MOGAD without the antibody testing described in Assessment & Diagnosis.
Three flavours of optic neuritis worth telling apart early
Typical (MS-associated or idiopathic) optic neuritis
Unilateral in the great majority of cases, usually retrobulbar with a normal-appearing disc, moderate vision loss (median nadir around 20/60), and — reassuringly — the best visual prognosis of any subtype, with most patients returning close to their baseline acuity.[4][1]
MOG-IgG-associated disease (MOGAD)
Bilateral more often than not (100% of cases in one cohort, whether simultaneous or closely sequential), younger median age, prominent disc edema, and — despite a more severe nadir (median around 20/200) — a good final visual outcome (median around 20/25) once treated; the trade-off is a genuinely high relapse rate.[4]
AQP4-IgG-positive NMOSD
The subtype most important not to miss: older median age at onset, more severe vision loss that frequently does not fully recover (light perception or worse at presentation and at follow-up in two-thirds of one cohort), a disc that typically looks unremarkable even with severe visual loss, and a strong association with longitudinally extensive transverse myelitis.[4] This is the subtype where early escalation beyond standard corticosteroid therapy (see Choose Initial Treatment) genuinely changes outcomes.
Two mechanistic phenomena worth explaining to patients
Uhthoff's phenomenon is a transient worsening of vision (or of other neurologic symptoms) with an increase in body temperature — exercise, a hot shower or bath, a fever, or a hot environment — reflecting temperature-sensitive conduction slowing along a demyelinated axon rather than new or worsening inflammation. Counselling patients about this specifically, and by name, matters: without it, a patient can reasonably interpret hot-shower-induced blurring as a relapse or a sign that treatment has failed, when it is neither. The Pulfrich phenomenon — a misperception of the trajectory of a moving object (classically, a swinging pendulum appears to trace an elliptical rather than a straight path) — reflects an interocular conduction-time difference between the affected and unaffected optic nerves, and can persist for months after otherwise good visual recovery; it is harmless but can be genuinely disorienting, and is worth naming explicitly if a patient describes it.
Natural history — most patients recover a great deal, with or without treatment
The natural history of a first episode of typical optic neuritis is, on the whole, reassuring: in the Canadian case series above, roughly 95% of patients returned to their baseline central visual acuity, a figure broadly consistent with the original Optic Neuritis Treatment Trial's long-term data.[1] This is precisely why the treatment decision in Choose Initial Treatment is framed as a genuine, informed choice about the speed of recovery rather than a decision that determines whether a patient recovers at all.
Risk Factors
- Female sex — 67% of cases in the largest modern population-based cohort, and a similarly strong female predominance within the MS-associated and MOGAD subtypes specifically (though AQP4-IgG-positive NMOSD in that same cohort was 100% female).[4]
- Age in the 20s to 40s for typical, MS-associated optic neuritis (median 37 years); MOGAD trends notably younger (median 26 years in the same cohort), while AQP4-IgG-positive NMOSD trends older (median 54 years) — age itself is a genuine clue toward which subtype is more likely.[4]
- A personal history of a prior demyelinating event, or an established diagnosis of MS, NMOSD, or MOGAD — a new optic neuritis episode in a patient with a known diagnosis still needs the same urgent assessment as a first episode, both to confirm it truly is a recurrence and to reassess treatment (see Treatment Failure/Next Step).
- Known AQP4-IgG or MOG-IgG seropositivity from a prior episode — a strong predictor that a new episode of visual loss is a recurrence of the same antibody-mediated disease rather than a new, unrelated diagnosis, and a reason to involve neurology early rather than treating empirically as typical optic neuritis.
- No single identifiable trigger explains most cases — idiopathic optic neuritis (no systemic cause found despite a reasonable workup) remains a substantial share of presentations (29% in the cohort above) even after MS-associated and antibody-defined cases are accounted for.[4]
Red Flags & Refer
Any patient with new, subacute vision loss consistent with optic neuritis needs urgent (same-day or next-available) ophthalmology or neuro-ophthalmology assessment, plus an urgent referral pathway to neurology for MRI-based workup. This is not a "start a drop and reassess in a week" presentation — the differential includes at least one true same-day emergency for the fellow eye, and the diagnostic workup itself is genuinely time-sensitive for risk-stratifying the patient's future.
Beyond the core triad, specific findings should raise particular urgency or a specific alternate diagnosis:
- Age over 50-55, especially with minimal or no pain, jaw claudication, scalp tenderness, new headache, or systemic symptoms (fever, weight loss, malaise): reconsider arteritic anterior ischemic optic neuropathy from giant cell arteritis (temporal arteritis) — a fundamentally different, same-day emergency that threatens the fellow eye and is treated with urgent high-dose corticosteroids and same-day inflammatory markers (ESR/CRP), started empirically before temporal artery biopsy confirms the diagnosis, not after.
- Absence of a relative afferent pupillary defect in a patient with unilateral or clearly asymmetric vision loss: reconsider the diagnosis rather than documenting it as a normal finding (see Recognize the Condition).
- Bilateral, simultaneous vision loss: atypical for typical MS-associated optic neuritis (only 29% bilateral in the largest cohort) and should raise suspicion for MOGAD (100% bilateral in the same cohort) or, less commonly, a toxic, nutritional, infectious, or hereditary optic neuropathy.[4]
- Severe vision loss at presentation — light perception or worse: raises concern for AQP4-IgG-positive NMOSD, where two-thirds of one cohort had light perception or worse both at presentation and at follow-up, and where earlier escalation beyond standard corticosteroids genuinely changes outcomes (see Choose Initial Treatment).[4]
- No improvement at all within the expected recovery window, or continued worsening beyond about two weeks: reconsider the diagnosis entirely — a compressive lesion (tumour, aneurysm) does not spontaneously improve the way inflammatory optic neuritis does, and dedicated orbital imaging with contrast is needed to exclude one.
- Optic disc pallor without a preceding history of swelling, or a slowly progressive rather than subacute course: favours a chronic compressive, toxic, nutritional, or hereditary process over acute inflammatory optic neuritis.
- New neurologic symptoms alongside the visual loss — limb weakness or numbness, a sensory level, bladder or bowel dysfunction, brainstem symptoms (double vision, vertigo, dysarthria) — raise concern for a myelitis or brainstem event occurring alongside the optic neuritis, seen with both MS and, especially, NMOSD, and warrant the same urgent neurology involvement.
Assessment & Diagnosis
Diagnosis is clinical — MRI is the pivotal next step, not just a confirmatory afterthought
Optic neuritis is fundamentally a clinical diagnosis, made from the history and examination pattern in Recognize the Condition.[1] What follows immediately after — MRI of the brain and orbits with contrast and fat suppression — is not simply confirmatory. It serves two distinct, equally important purposes: demonstrating an enhancing, T2-hyperintense lesion of the optic nerve itself (supporting the diagnosis and helping exclude a compressive lesion in the same study), and, separately, examining the rest of the brain for white-matter lesions that are the single strongest predictor of the patient's own future risk of MS.[1][5]
MRI-based MS risk stratification — the ONTT's central, durable finding
The Optic Neuritis Treatment Trial's 15-year follow-up remains the definitive long-term data on this question. The overall cumulative probability of developing MS by 15 years after a first episode of optic neuritis was 50% — but that risk is not evenly distributed, and baseline brain MRI is what separates a genuinely low-risk patient from a genuinely high-risk one.[5]
| Baseline brain MRI finding | Approximate cumulative MS risk at 15 years |
|---|---|
| One or more T2-hyperintense white-matter lesions (≥3 mm) | About 72% |
| No brain lesions | About 25% |
Among the MRI-negative group specifically — the more reassuring group — a few baseline features are independently associated with an even lower likelihood of eventual MS: male sex, optic disc swelling at presentation, and atypical clinical features of the optic neuritis itself.[5] A genuinely important, easy-to-misstate nuance about treatment and this risk: an earlier analysis from the same trial found that intravenous methylprednisolone modestly reduced the 2-year rate of a new MS-defining clinical event specifically in the subgroup with baseline brain lesions — but this apparent protective effect did not persist at longer-term follow-up, and MRI lesion status, not treatment choice, is what actually predicts the patient's durable 15-year risk.[3][5] In practice, this means IV corticosteroids should be discussed with a patient purely on the basis of hastening visual recovery (see Choose Initial Treatment), not on the expectation that they meaningfully change a patient's long-term MS risk.
When to send AQP4-IgG and MOG-IgG serology
Not every patient needs antibody testing at presentation — a typical, unilateral, moderate first episode in an adult with a normal disc is reasonably managed as typical optic neuritis while awaiting MRI. Antibody testing becomes clearly appropriate, and should not be deferred, when any atypical feature is present:[4][6][7]
- Bilateral or rapidly sequential involvement.
- Severe vision loss — light perception or worse — at presentation.
- Little or no visual recovery by the expected timeframe.
- Prominent optic disc edema, especially with peripapillary hemorrhage.
- A longitudinally extensive optic nerve lesion on MRI (involving more than half the nerve's length), perineural enhancement, or extension of the lesion into the optic chiasm.
- Recurrent episodes, in either eye.
- Concurrent symptoms suggesting myelitis (limb weakness, a sensory level, bladder/bowel dysfunction) or an area-postrema syndrome (intractable hiccups, nausea, vomiting).
AQP4-IgG is tested by a cell-based assay and, when positive in the correct clinical context, is essentially diagnostic of NMOSD.[6] MOG-IgG is likewise tested by a cell-based assay, and the 2023 International MOGAD Panel criteria require a compatible core clinical event (optic neuritis is one of six recognized core presentations), a positive MOG-IgG result, and exclusion of a better alternative diagnosis.[7] Both results meaningfully change the treatment and counselling plan (see Special Populations) and should not be treated as a research curiosity ordered only after standard treatment has already failed.
Cerebrospinal fluid analysis
CSF analysis is not required for every patient but is a reasonable part of the workup, particularly when the diagnosis is uncertain or when supporting evidence for MS is wanted alongside the MRI: CSF-specific oligoclonal bands support an underlying diagnosis of MS and factor into the neurologist's overall risk assessment and, where relevant, the formal MS diagnostic criteria applied to the case.
Differentiating optic neuritis from its two most consequential mimics
| Feature | Typical optic neuritis | Arteritic AION (giant cell arteritis) | Compressive lesion (e.g., tumour) |
|---|---|---|---|
| Typical age | 20s-40s | Over 50-55, usually over 70 | Any age |
| Onset | Subacute, hours to days | Sudden, often on waking | Gradual, progressive over weeks to months |
| Pain | Present in most cases, worse with eye movement | Usually absent or minimal; may have jaw claudication/scalp tenderness instead | Usually absent |
| Visual field pattern | Central/cecocentral scotoma (variable) | Altitudinal defect | Variable; often progressive |
| Optic disc | Normal in most (retrobulbar); swollen in a minority | Swollen, often pale, sometimes with hemorrhage | Normal early; pale (atrophic) later |
| Course without specific treatment | Spontaneous improvement is typical | Does not spontaneously improve; fellow eye at imminent risk | Progressive; does not spontaneously improve |
| Key test | MRI brain/orbits with contrast | ESR/CRP, temporal artery biopsy | MRI/CT with contrast |
Treatment Targets
- Confirm the diagnosis promptly and exclude its two most consequential mimics — arteritic AION (giant cell arteritis) and a compressive lesion — rather than assuming every case of subacute vision loss with pain is straightforward optic neuritis.
- Use MRI of the brain and orbits not only to support the diagnosis but to genuinely risk-stratify the patient for future MS, and communicate that risk honestly and proportionately.
- Offer intravenous corticosteroid therapy as an informed, elective choice to hasten visual recovery — while being explicit that it does not change the ultimate visual outcome.
- Avoid a genuinely harmful, counterintuitive error: treating with oral corticosteroids alone, which provides no benefit and increases the risk of a new attack.
- Recognize atypical features early enough to test AQP4-IgG and MOG-IgG and involve neurology before, rather than only after, standard treatment has failed.
- Escalate arteritic AION (giant cell arteritis) as the same-day emergency it is, protecting the fellow eye rather than treating it on the same timeline as typical optic neuritis.
- Support the patient through what is, for many, a frightening entry point into an uncertain conversation about MS — with accurate information delivered without either false reassurance or unnecessary alarm.
Choose Initial Treatment
IV methylprednisolone hastens recovery only — it does not change the outcome — and oral prednisone alone is never appropriate
For a patient with confirmed or strongly suspected typical acute optic neuritis, intravenous corticosteroid therapy is an elective option offered specifically to speed up visual recovery by roughly 4-6 weeks; it does not improve the final visual outcome at 6 months to 10 years compared with no treatment at all.[2][1] This should be presented to the patient as a genuine, informed choice about the pace of recovery, not as a treatment that changes whether — or how completely — they will recover.
Oral prednisone alone, at any dose, is never appropriate initial therapy. The Optic Neuritis Treatment Trial found that oral prednisone given without a preceding IV course provided no benefit over placebo for either recovery speed or final outcome, and — the genuinely counterintuitive finding — significantly increased the risk of a new episode of optic neuritis in either eye.[3] This is a real, well-established exception to the general pattern of "more corticosteroid is more corticosteroid" — the specific regimen and route matter.
The IV methylprednisolone regimen
The regimen studied in the ONTT, and the one still in common use, is methylprednisolone 1 g IV once daily for 3 consecutive days, typically followed by an oral prednisone taper (1 mg/kg/day for 11 days) directed by the treating specialist.[1][2] The oral component here is fundamentally different from the "oral prednisone alone" regimen warned against above — it follows, rather than replaces, the IV pulse, and this distinction is worth making explicitly clear to the patient and to anyone reconciling the regimen against this chapter's Pharmacologic Treatment Options.
Steroid-refractory, severe, or NMOSD-suspicious disease
For patients who do not respond adequately to corticosteroids, or who present from the outset with features suggesting AQP4-IgG-positive NMOSD (severe vision loss, bilateral involvement, an unremarkable disc despite severe loss — see Recognize the Condition and Assessment & Diagnosis), plasma exchange is a reasonable specialist-directed escalation, and should be considered early in a severe or NMOSD-suspicious presentation rather than only after a full corticosteroid course has already failed. Intravenous immunoglobulin (IVIG) is a reasonable alternative where apheresis access is not available, though its evidence base for this specific indication is weaker than that for plasma exchange.
Arteritic AION (giant cell arteritis) — a different disease, treated on a different timeline
When the presentation and risk profile (see Red Flags for Referral) instead suggest arteritic anterior ischemic optic neuropathy from giant cell arteritis, management is urgent, high-dose corticosteroid therapy started the same day — often at doses considerably higher than the optic neuritis regimen above — specifically to protect the fellow eye, and is not delayed for temporal artery biopsy confirmation. This is a genuinely distinct disease process from optic neuritis, addressed here only to the extent needed to keep the two apart; definitive giant cell arteritis management is outside this chapter's scope.
Non-Pharmacologic Treatment
- Arrange urgent (same-day or next-available) ophthalmology or neuro-ophthalmology assessment for any suspected case — this is not a presentation to manage with reassurance and a follow-up appointment in a week.
- Arrange MRI of the brain and orbits with contrast promptly, ideally before or at the time treatment is started, since it drives both diagnosis confirmation and MS-risk counselling.
- Counsel explicitly on Uhthoff's phenomenon before it happens — a patient who understands that heat-related transient blurring is expected and reversible is far less likely to interpret it as a relapse or treatment failure (see Recognize the Condition).
- Discuss driving safety honestly if vision is currently insufficient for safe driving, including any applicable reporting obligations, rather than leaving this unaddressed until the patient raises it.
- Address the psychological impact directly — many patients arrive already having searched "optic neuritis" and found the MS association themselves. Acknowledge the uncertainty honestly rather than offering premature reassurance ("it's probably nothing") or premature alarm ("this means you have MS") before the MRI-based workup is complete.
- Arrange low-vision or visual rehabilitation support for the minority of patients with incomplete recovery, rather than assuming every patient reaches the roughly 95% return-to-baseline outcome typical of the group as a whole.[1]
- Do not delay referral to "wait and see how it goes" — while spontaneous improvement is genuinely common, the differential (arteritic AION, a compressive lesion) and the value of early MRI are both time-sensitive.
- Coordinate closely with neurology once MRI results are available — the ophthalmologic and neurologic threads of this diagnosis (optic nerve treatment and MS-risk counselling/workup) proceed in parallel, not sequentially.
Special Populations
Suspected or confirmed AQP4-IgG-positive NMOSD
This is the subtype where getting the diagnosis right early changes outcomes the most. Visual loss tends to be more severe and less likely to fully recover — two-thirds of one cohort had light perception or worse both at presentation and at follow-up — and the optic disc typically looks unremarkable even with profound loss, which can be falsely reassuring on cursory examination.[4] Plasma exchange should be considered early — not reflexively after a full corticosteroid course has already failed — in a severe or NMOSD-suspicious presentation (see Choose Initial Treatment).[6] Once AQP4-IgG-positive NMOSD is confirmed, neurology typically initiates long-term relapse-prevention therapy (for example rituximab, azathioprine, mycophenolate mofetil, or one of the newer complement- or IL-6-targeted biologics approved specifically for AQP4-IgG-positive disease). A genuinely important safety point: unlike MS, NMOSD does not respond to — and can be worsened by — several MS disease-modifying therapies, including interferon beta, fingolimod, and natalizumab, which is exactly why accurate antibody-based diagnosis before starting any long-term therapy matters so much; a patient misdiagnosed with MS and started on the wrong agent can suffer a genuinely worse disease course as a direct result.
Suspected or confirmed MOGAD
MOG-IgG-associated disease trends younger, is bilateral more often than not, and produces more prominent disc swelling than typical optic neuritis — but, reassuringly, tends to recover well with treatment (median final visual acuity around 20/25 in one cohort, despite a more severe nadir around 20/200).[4][7] The trade-off is a genuinely high relapse rate (roughly two-thirds of patients in the same cohort had more than one attack), and MOGAD often behaves as a steroid-dependent disease — relapsing as the corticosteroid dose is tapered — which is why neurology may use a considerably more prolonged oral taper than the standard 11-day ONTT-style course, or add a steroid-sparing agent, for patients with a relapsing course.[4]
Pediatrics
Optic neuritis in children differs from the typical adult presentation in ways worth anticipating: bilateral involvement is more common than in adults, a preceding or concurrent viral illness (a para-infectious pattern) is common, and disc swelling is seen more often than in the typical adult retrobulbar presentation. MOG-IgG-associated disease is disproportionately represented in the pediatric population relative to adults. The same urgent referral and MRI-based workup principles apply regardless of age; involve pediatric neurology and pediatric ophthalmology/neuro-ophthalmology early given the differences in typical presentation and in long-term MS-conversion risk between pediatric- and adult-onset disease.
Pregnancy and breastfeeding
A short IV corticosteroid course for a vision-threatening or vision-limiting indication is generally not withheld in pregnancy on the basis of the pregnancy alone — discuss the specific regimen and timing with obstetrics, particularly around the trimester and any other maternal or fetal considerations. MS relapse patterns are well documented to change across pregnancy and the postpartum period; involve the patient's neurologist (or arrange one) early if MS is confirmed or strongly suspected, both for this pregnancy and for any future family planning discussion around long-term disease-modifying therapy, several of which are not compatible with pregnancy.
Older adults — arteritic AION vigilance
In any patient over roughly 50-55 years old presenting with acute vision loss, actively screen for the features that distinguish arteritic AION from typical optic neuritis (see Assessment & Diagnosis) — minimal or absent pain, an altitudinal rather than central field defect, jaw claudication, scalp tenderness, and systemic symptoms — and have a low threshold to obtain same-day inflammatory markers and urgent ophthalmology assessment. Missing this distinction risks the fellow eye's vision, on a timescale of hours to days, not weeks.
Recurrent optic neuritis and CRION
A minority of patients experience recurrent, steroid-responsive but steroid-dependent optic neuritis without ever testing positive for AQP4-IgG or MOG-IgG — sometimes referred to as chronic relapsing inflammatory optic neuropathy (CRION). Any recurrence, in either eye, should prompt (or repeat) AQP4-IgG and MOG-IgG testing if not already done, and involvement of neuro-ophthalmology or neurology for consideration of long-term steroid-sparing immunotherapy rather than repeated short corticosteroid courses alone (see Treatment Failure/Next Step).
Monitoring & Follow-Up
- Track visual recovery against the expected trajectory — most improvement occurs over the first several weeks, though some continued improvement can occur for months; formal follow-up (visual acuity, colour vision, visual field, and, where available, optical coherence tomography of the retinal nerve fibre layer to objectively track axonal loss) is arranged by ophthalmology or neuro-ophthalmology.
- Confirm the patient never received oral prednisone alone, without a preceding IV course, as part of medication reconciliation — this specific error is worth actively checking for, not just avoiding prospectively (see Common Errors to Avoid).
- Maintain neurology follow-up for MS-risk counselling and monitoring based on the baseline MRI result, regardless of how well the eye itself recovers — the MRI-based risk described in Assessment & Diagnosis does not resolve just because vision does.[5]
- Watch specifically for a second clinical event — a new neurologic symptom, or a new lesion on interval MRI — as the trigger for a formal MS diagnosis discussion and, where appropriate, initiation of disease-modifying therapy by neurology.
- Treat any new episode of vision loss, in either eye, as a genuine recurrence requiring the same urgent workup as a first episode — not something to be managed by reflexively repeating the same corticosteroid regimen — and use it as a prompt to send or repeat AQP4-IgG/MOG-IgG testing if not already done.
- During any corticosteroid course, monitor blood glucose (particularly in patients with diabetes or risk factors for it), sleep and mood changes, and gastrointestinal symptoms; a short course rarely needs bone-protective or GI-prophylactic therapy but individual risk factors should be considered.
Common Errors to Avoid
- Treating with oral prednisone alone, without a preceding IV course — the ONTT found this specifically increases the risk of a new optic neuritis episode, a genuine, counterintuitive harm rather than simply "a weaker version" of the effective regimen.[3]
- Telling a patient that IV corticosteroids will improve their final visual outcome — they hasten recovery speed only, and setting the wrong expectation undermines genuinely informed, shared decision-making.[2]
- Skipping or delaying MRI of the brain and orbits with contrast — it is the single most important test for both diagnosis confirmation and MS-risk stratification, not an optional add-on once the eye has already recovered.
- Dismissing the absence of an RAPD in unilateral vision loss as a normal or unremarkable finding rather than a prompt to reconsider the diagnosis.
- Anchoring on "optic neuritis" in an older patient without actively screening for arteritic AION/giant cell arteritis — a fundamentally different, same-day emergency for the fellow eye.
- Assuming a normal-appearing optic disc argues against the diagnosis — most typical optic neuritis is retrobulbar with a normal disc at presentation.
- Delaying urgent referral because spontaneous improvement is common — the differential (arteritic AION, a compressive lesion) and the MS-risk-stratification opportunity are both genuinely time-sensitive, independent of how the eye itself is expected to do.
- Failing to send AQP4-IgG and MOG-IgG serology in an atypical presentation (bilateral, severe, poorly recovering, disc swelling out of proportion) and instead treating every case as typical, MS-associated optic neuritis.
- Making a definitive statement that a patient "has" or "does not have" MS based on a single optic neuritis episode before the MRI-based (and, where relevant, CSF-based) workup is complete.
- Under-addressing the psychological impact of an uncertain MS-risk conversation, or over-reassuring a patient before the workup that actually establishes their individual risk is complete.
- Repeating or prolonging corticosteroid courses for recurrent episodes without escalating to antibody testing or specialist reassessment.
- Misinterpreting Uhthoff's phenomenon — heat-related transient visual blurring — as a true relapse or a sign that treatment has failed.
Clinical Decision Algorithm
Drug Tables
How to use this table: Doses are adult doses and require patient-specific confirmation (renal/hepatic function, weight, allergy history). Pediatric dosing is weight-based per the current product monograph unless stated. Drug pricing is intentionally omitted. Select any drug name to open its complete Pharmasist Drug Database page.
Acute Optic Neuritis — Corticosteroid Therapy
Intravenous corticosteroid therapy hastens visual recovery by weeks; it does not change the final visual outcome. This is an elective, shared decision with the patient, not a mandatory intervention.
| Drug | Dosage | Adverse effects | Drug interactions | Comments |
|---|---|---|---|---|
| Methylprednisolone sodium succinate | IV pulse (adults): 1 g IV once daily for 3 consecutive days Oral taper (optional, per ONTT protocol): prednisone 1 mg/kg/day (typically up to 60-80 mg/day) for 11 days, tapered per the treating specialist's direction | Insomnia, mood changes/agitation, hyperglycemia, GI upset, metallic taste during infusion; rare avascular necrosis with repeated high-dose courses | Additive hyperglycemia with other agents affecting glucose control; live vaccines deferred during a course | Speeds recovery by about 4-6 weeks; no effect on visual acuity at 6 months to 10 years. Always given as the IV pulse — the oral component, when used, follows the IV course rather than replacing it. |
Not Recommended — Oral Corticosteroid Monotherapy
Level-A-quality randomized trial evidence against use, not a judgment call — this is a genuine exception where the same drug class is beneficial by one route and harmful by another in the same disease.
| Drug | Dosage | Adverse effects | Drug interactions | Comments |
|---|---|---|---|---|
| Oral prednisone (given alone, without preceding IV methylprednisolone) | Any dose, as sole therapy: Not recommended | Same corticosteroid adverse-effect profile as any oral course, without a corresponding benefit | Not applicable — not recommended for this indication | In the ONTT, oral prednisone alone (1 mg/kg/day for 14 days) gave no benefit over placebo for either recovery speed or final visual outcome, and significantly increased the risk of a new episode of optic neuritis in either eye. |
Steroid-Refractory or Severe Disease (Specialist-Directed)
Reserved for patients who do not respond to corticosteroids, or who present with severe, bilateral, or NMOSD-suspicious features from the outset; consider early rather than only after a full course of steroids has already failed.
| Drug | Dosage | Adverse effects | Drug interactions | Comments |
|---|---|---|---|---|
| Plasma exchange (plasmapheresis) | Adults: Typically 5-7 exchanges over 10-14 days, via a large-bore catheter, specialist- and apheresis-resource-directed | Hypotension, catheter-related infection or thrombosis, citrate-related hypocalcemia, coagulopathy | Removes recently administered IV drugs and some coagulation factors — coordinate timing of other IV medications with the apheresis team | Consider early in severe or AQP4-IgG-suspected presentations rather than reflexively repeating or prolonging corticosteroids. |
| Immunoglobulin (Human) — IVIG | Adults: Total 2 g/kg IV, divided over 2-5 days | Headache, aseptic meningitis, renal impairment (especially sucrose-containing formulations), thromboembolism, anaphylaxis in IgA-deficient patients | May reduce the efficacy of live vaccines given within about 3 months of infusion | A reasonable alternative to plasma exchange where apheresis access is unavailable; weaker specific evidence base for optic neuritis than plasma exchange. |
Long-Term Relapse-Prevention Therapy (Diagnosis-Specific, Neurology-Initiated)
Selecting and dosing long-term relapse-prevention therapy is a neurology-led decision made only once the underlying diagnosis (MS, AQP4-IgG-positive NMOSD, or MOGAD) is established — genuinely outside this chapter's own scope, but summarized here because the choice of agent is diagnosis-specific and getting the diagnosis wrong before starting one can cause real harm (see comments).
| Drug | Dosage | Adverse effects | Drug interactions | Comments |
|---|---|---|---|---|
| MS disease-modifying therapy (e.g., interferon beta, glatiramer acetate, dimethyl fumarate, teriflunomide, fingolimod, natalizumab, ocrelizumab, and others) | —: Agent-specific; neurology-directed | Varies widely by agent | Varies widely by agent | Initiated by neurology once a diagnosis of clinically definite MS is made, or per an individualized risk discussion after a first demyelinating event; agent-specific selection and monitoring are outside this chapter's scope. |
| AQP4-IgG-positive NMOSD relapse-prevention therapy (e.g., rituximab, azathioprine, mycophenolate mofetil, eculizumab, satralizumab, inebilizumab) | —: Agent-specific; neurology-directed | Varies widely by agent | Varies widely by agent | Initiated by neurology once AQP4-IgG-positive NMOSD is confirmed. Several MS therapies — interferon beta, fingolimod, and natalizumab among them — can worsen NMOSD, which is exactly why accurate antibody-based diagnosis before starting long-term therapy matters so much. |
| MOGAD relapse-prevention therapy (e.g., a prolonged oral corticosteroid taper, azathioprine, mycophenolate mofetil, IVIG, rituximab) | —: Agent-specific; neurology-directed | Varies widely by agent | Varies widely by agent | Considered by neurology for patients with relapsing MOGAD, given the disease's tendency toward steroid-dependent recurrence even though individual attacks are often very steroid-responsive. |
References
- A 30-year-old woman with vision loss and painful eye movements — CMAJ, Canadian Medical Association Journal (Micieli JA, Margolin E). CMAJ 2015;187(9):673-675
- A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis — New England Journal of Medicine (Beck RW, Cleary PA, Anderson MM Jr, et al; Optic Neuritis Study Group). N Engl J Med 1992;326(9):581-588
- The effect of corticosteroids for acute optic neuritis on the subsequent development of multiple sclerosis — New England Journal of Medicine (Beck RW, Cleary PA, Trobe JD, et al; Optic Neuritis Study Group). N Engl J Med 1993;329(24):1764-1769
- Population-based incidence of optic neuritis in the era of aquaporin-4 and myelin oligodendrocyte glycoprotein antibodies — American Journal of Ophthalmology (Hassan MB, Stern C, Flanagan EP, Pittock SJ, Kunchok A, Foster RC, Jitprapaikulsan J, Hodge DO, Bhatti MT, Chen JJ). Am J Ophthalmol 2020;220:110-114
- Multiple sclerosis risk after optic neuritis: final Optic Neuritis Treatment Trial follow-up — Archives of Neurology (Optic Neuritis Study Group). Arch Neurol 2008;65(6):727-732
- International consensus diagnostic criteria for neuromyelitis optica spectrum disorders — Neurology, American Academy of Neurology (Wingerchuk DM, Banwell B, Bennett JL, et al; International Panel for NMO Diagnosis). Neurology 2015;85(2):177-189
- Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: International MOGAD Panel proposed criteria — The Lancet Neurology (Banwell B, Bennett JL, Marignier R, et al; International MOGAD Panel). Lancet Neurol 2023;22(3):268-282
Professional reference only. Apply clinical judgment and verify patient-specific decisions against current authoritative guidance and product information.